<DOC>
	<DOC>NCT00763529</DOC>
	<brief_summary>This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone propionate cream 0.05% (twice daily) by the end of Day 4 and Day 8 in the management of Indian patients with localized psoriasis.</brief_summary>
	<brief_title>Elocon vs Fluticasone in Localized Psoriasis (P03197)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>&gt;=18 years of age Written informed consent Having localized psoriasis (not more than 56 patches) Total size of all patches should be below 8" x 8" Each patient should exhibit any of the following 4 signs of dermatoses: erythema palpability scaling itching (pruritus) Each of the above signs would be grades according to the following scale: 0 = none 1. = slight 2. = moderate 3. = severe The total Disease Severity Score (ie, the sum of the scores for each of the signs) should be at least 6 (indicative of a moderate to severe disease status) Pregnancy or lactation Hypersensitivity to any of the components of the test medication Signs of atrophy in the target area Lesions on palms, soles, and scalp Individuals who may require medications that might affect the natural course of the disease Not having used systemic corticosteroids or antimetabolites or any other topical corticosteroid within 2 weeks prior to enrollment in the study Concomitant tuberculosis/viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>